Leap Therapeutics: A Buy On Near-Term Data Catalysts In Stomach And Colon Cancer
- Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early trial data in GI cancers. LPTX has a short operational runway with less than a year's worth of funds, making future funding a critical concern. Key phase 2 trial readouts for DKN-01 are expected in 2025, which could significantly impact the company's valuation and investment potential.
- 01/06/2025
|
Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass. , Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 01/06/2025
|
Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference
- CAMBRIDGE, Mass. , Nov. 26, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 11/26/2024
|
Leap Therapeutics Reports Third Quarter 2024 Financial Results
- CAMBRIDGE, Mass. , Nov. 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2024.
- 11/13/2024
|
Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
- CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment of 188 patients has been completed in the randomized controlled Part B of the DeFianCe study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (CRC).
- 09/30/2024
|
3 Trending Biotech Penny Stocks
- Biotech stocks are some of my favorite stocks to watch and invest in for a couple of reasons.
- 08/22/2024
|
Leap Therapeutics Reports Second Quarter 2024 Financial Results
- CAMBRIDGE, Mass. , Aug. 12, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2024.
- 08/12/2024
|
Leap Therapeutics Reports First Quarter 2024 Financial Results
- CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2024.
- 05/13/2024
|
Leap Therapeutics Announces $40 Million Private Placement
- Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development program CAMBRIDGE, Mass. , April 11, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise of the pre-funded warrants, in a private placement.
- 04/11/2024
|
Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks
- Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 03/20/2024
|
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.
- 03/18/2024
|
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
- 30% ORR and 93% DCR across heterogenous second-line CRC patients treated with DKN-01 plus bevacizumab and chemotherapy Subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% ORR, 100% DCR, and preliminary median PFS of 9.4 months. Leap to host conference call to report additional clinical data including further subgroup analyses on Tuesday, January 23, 2024 at 8:30 a.m.
- 01/16/2024
|
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
- CAMBRIDGE, Mass. , Jan. 3, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 01/03/2024
|
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
- CAMBRIDGE, Mass. , Jan. 2, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer.
- 01/02/2024
|
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
- CAMBRIDGE, Mass. , Dec. 11, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium taking place in San Francisco, CA and virtually on January 18-20, 2024.
- 12/11/2023
|
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
- CAMBRIDGE, Mass. , Nov. 21, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 11/21/2023
|
Leap Therapeutics Reports Third Quarter 2023 Financial Results
- CAMBRIDGE, Mass. , Nov. 13, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023.
- 11/13/2023
|
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- NEW YORK, NY, October 24, 2023 – The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector.
- 10/24/2023
|
Leap Therapeutics to Participate at Upcoming Investor Conferences
- CAMBRIDGE, Mass. , Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 09/05/2023
|
Leap Therapeutics Reports Second Quarter 2023 Financial Results
- CAMBRIDGE, Mass. , Aug, 14, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023.
- 08/14/2023
|
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients
- CAMBRIDGE, Mass., July 12, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study.
- 07/12/2023
|
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting
- 19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in overall mITT population, including 86% ORR in PD-L1-low patients CAMBRIDGE, Mass. , May 25, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene's tislelizumab and chemotherapy, at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 2-6, 2023.
- 05/25/2023
|
3 Hot Penny Stocks To Watch Under $1, Time To Buy?
- Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
- 05/18/2023
|
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
- NEW YORK , Jan. 30, 2023 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. Weiss Law 305 Broadway, 7th Floor New York, NY 10007 (212) 682-3025 (888) 593-4771 stockinfo@weisslawllp.com Evoqua Water Technologies Corp. (NYSE: AQUA) Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Evoqua Water Technologies Corp. (NYSE: AQUA) in connection with the proposed acquisition of AQUA by Xylem Inc. ("Xylem").
- 01/30/2023
|
Mergers and Acquisitions in 2023 Off To A Strong Start
- Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $6 billion sale of LHC Group Inc. (Nasdaq: LHCG) to UnitedHealth (NYSE: UNH) and the $8 billion sale of Signify Health Inc. (NYSE: SGFY) to CVS Health Co. (NYSE: CVS).
- 01/27/2023
|
LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders
- NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders. Halper Sadeh encourages Leap shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Leap and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Leap shareholders; and (2) disclose all material information necessary for Leap shareholders to adequately assess and value the merger consideration. On behalf of Leap shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages Leap shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
- 01/24/2023
|
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
- 55% ORR, 73% DCR, and 7.7 month PFS in DKK1-high/PD-L1-high second-line gastric cancer patients DKN-01 also demonstrated preclinical tumor regression data in CRC models supporting ongoing clinical trial CAMBRIDGE, Mass. , Nov. 7, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal adenocarcinoma (GEA) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.
- 11/07/2022
|
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
- CAMBRIDGE, Mass. , Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from Part B of the DisTinGuish Study evaluating DKN-01 in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in second-line gastroesophageal junction/gastric (GEJ/G) cancer patients whose tumors express high levels of DKK1 (DKK1-high) at the Society of Immunotherapy for Cancer (SITC) 37th Annual Meeting being held in Boston, MA on November 8-12, 2022.
- 10/05/2022
|
Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress
- Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding benchmarks in the overall population and in DKK1 and PD-L1 subgroups Median Overall Survival is not mature with only 44% of patients deceased as of the data cut Enrollment ongoing in the study of DKN-01 plus Tecentriq® (atezolizumab) in second- or third-line oesophagogastric cancer patients, activity in DKK1-high patients consistent with prior studies with pembrolizumab or tislelizumab CAMBRIDGE, Mass. , Sept. 4, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma (GEA) from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology (ESMO) Congress 2022 being held on September 9-12.
- 09/04/2022
|
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
- Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
- 07/08/2022
|
Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
- Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate cancer market could reach $12 billion by 2025.
- 06/27/2022
|
Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April
- Check these three penny stocks out for your watchlist right now The post Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/19/2022
|
Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference
- CAMBRIDGE, Mass., Jan. 24, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 01/24/2022
|
Why Leap Therapeutics Stock Is Surging Today
- Positive clinical trial results are giving investors a reason to cheer.
- 01/19/2022
|
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
- Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
- 01/19/2022
|
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
- CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January 20-22, 2022.
- 01/18/2022
|
2 Risky Growth Stocks That Could Make You Filthy Rich
- These two biotech stocks are set to report key clinical data later this year.
- 01/16/2022
|
7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
- Short squeeze penny stocks to watch right now. The post 7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/11/2022
|
Top Penny Stocks To Buy According To Analysts & Targets Up To 615%
- Penny stocks with hight hopes from analysts. The post Top Penny Stocks To Buy According To Analysts & Targets Up To 615% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/31/2021
|
Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch
- Looking for short squeeze penny stocks? Give these 5 a look.
- 11/30/2021
|
Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
- Shares of this small oncology company have risen by 45% over the past three months, yet are down 10% over the past month.
- 11/29/2021
|
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
- Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/29/2021
|
Best Short Squeeze Penny Stocks To Buy? 4 To Watch Right Now
- Are these the top penny stocks to watch for a short squeeze? The post Best Short Squeeze Penny Stocks To Buy?
- 10/19/2021
|
Leap Therapeutics: Another Leap Coming Up
- Leap Therapeutics: Another Leap Coming Up
- 10/15/2021
|
Leap Therapeutics: All On The Line
- Leap Therapeutics is an early stage oncology company with a single active asset. Their single asset focuses on a pathway that is dysregulated in multiple cancers.
- 10/12/2021
|
5 Buy-Rated, Scorching-Hot Stocks All Trading Under $10
- While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
- 10/09/2021
|
3 Biotech Stocks That Surged in September
- Find out why last month was a big one for these three drugmakers.
- 10/05/2021
|
Leap Therapeutics, AstraZeneca Shares Get Boost From Cancer Presentations
- Leap Therapeutics Inc. ( LPTX , Financial) lived up to its name when it scored a big jump in stock price following its presentation at the recent European Society for Medical Oncology meeting. The Cambridge, Massachusetts-based microcap saw its shares climb 23% to $2.3650 after it reported new data from the study of its drug for treating gastroesophageal junction cancer.
- 09/29/2021
|
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
- CAMBRIDGE, Mass., Sept. 24, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 27,568,072 shares of its common stock, which includes the sale of an additional 4,740,000 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional shares, and of pre-funded warrants to purchase 8,771,928 shares of its common stock.
- 09/24/2021
|
Leap Therapeutics Announces Pricing of $90 million of Common Stock and Pre-Funded Warrants
- CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.85 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $2.849 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.
- 09/22/2021
|
Making Money With Penny Stocks During a Stock Market Crash
- Trading penny stocks in a down market? Here's three tips and tricks to use in your search The post Making Money With Penny Stocks During a Stock Market Crash appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/20/2021
|
Hot Penny Stocks to Buy Right Now? 3 For Your Watchlist
- Making a penny stocks watchlist in 2021? Here's three you should check out The post Hot Penny Stocks to Buy Right Now?
- 09/17/2021
|
Why Leap Therapeutics Shares Are Trading Higher Today
- Leap Therapeutics (NASDAQ:LPTX) shares are trading higher after the company announced it presented updated results for its DKN-01 plus tislelizumab which showed "compelling" activity in first-line patients with gastric, gastroesophageal junction cancer. Leap Therapeutics' stock is trading up 38.86% to a price of $2.68.
- 09/16/2021
|
Space Stocks: Why SPIR, ASTR, MNTS, RDW and SPCE Are Getting a Boost Today
- Space stocks are taking off on Thursday and it's all thanks to Elon Musk's SpaceX reaching a major milestone for commercial space travel. The post Space Stocks: Why SPIR, ASTR, MNTS, RDW and SPCE Are Getting a Boost Today appeared first on InvestorPlace.
- 09/16/2021
|
LPTX Stock: What Leap Therapeutics Investors Are Clicking Their Heels About Today
- Leap Therapeutics (LPTX) stock is on the move today following an update from the biotechnology company for recent clinical trial results. The post LPTX Stock: What Leap Therapeutics Investors Are Clicking Their Heels About Today appeared first on InvestorPlace.
- 09/16/2021
|
LPTX Stock: Why It Significantly Increased Today
- The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 27% during intraday trading today. This is why it happened.
- 09/16/2021
|
Leap Therapeutics Stock Is Moving Higher On Updated DKN-01 Combo Trial Data In Gastric Cancer
- Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ). The data were presented at the European Society for Medical Oncology (ESMO21) Congress.
- 09/16/2021
|
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
- CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.
- 09/16/2021
|
3 Top Penny Stocks to Watch That Are Trending Right Now
- Finding trending penny stocks can be a great strategy to use, here's three to watch The post 3 Top Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/14/2021
|
Uranium Stocks: Why CCJ, UUUU, UEC, URG, DNN and NXE Are Glowing Up today
- Uranium stocks are on the move today and it doesn't have anything to do with specific news from any of the companies in the space. The post Uranium Stocks: Why CCJ, UUUU, UEC, URG, DNN and NXE Are Glowing Up today appeared first on InvestorPlace.
- 09/13/2021
|
Why Are Leap Therapeutics Shares Trading Higher On Monday?
- Leap Therapeutics Inc (NASDAQ: LPTX) stock increased over 30% premarket as the investors are responding positively ahead of the Company's presentation of new data from the first-line cohort of the DisTinGuish study. The Phase 2a trial is evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ).
- 09/13/2021
|
LPTX Stock: Why It Increased Today
- The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased over 20% pre-market. This is why it happened.
- 09/13/2021
|
Leap Therapeutics to Present New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO 2021 Congress
- CAMBRIDGE, Mass., Sept. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.
- 09/13/2021
|
4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%
- These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/08/2021
|
Leap Therapeutics, Inc. (LPTX) Reports Q2 Loss
- Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of 7.69% and 0.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/13/2021
|
Leap Therapeutics Reports Second Quarter 2021 Financial Results and Upcoming Data Presentation
- CAMBRIDGE, Mass., Aug. 13, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2021 and provided upcoming company milestones.
- 08/13/2021
|
Leap Therapeutics to Present at the ESMO 2021 Virtual Congress
- CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's Ltd.
- 07/26/2021
|
Down 19.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Leap Therapeutics, Inc. (LPTX)
- Leap Therapeutics, Inc. (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 07/19/2021
|
Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
- CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 07/07/2021
|
Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
- CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
- 06/14/2021
|
Leap Therapeutics, Inc. (LPTX) Reports Q1 Loss, Lags Revenue Estimates
- Leap Therapeutics, Inc. (LPTX) delivered earnings and revenue surprises of -9.09% and -3.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/14/2021
|
Leap Therapeutics Reports First Quarter 2021 Financial Results
- CAMBRIDGE, Mass., May 14, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2021.
- 05/14/2021
|
Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment
- CAMBRIDGE, Mass. and WESTMINSTER, Colo.
- 05/12/2021
|
LPTX Stock: Over 2.5% Increase Pre-Market Explanation
- The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 2.5% pre-market. This is why it happened.
- 04/12/2021
|
Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
- CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the completion of enrollment for the first-line patient cohort in the DisTinGuish study, a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.
- 04/01/2021
|
LPTX Stock Price Increases Over 25% Pre-Market: Why It Happened
- The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 25% pre-market. This is why it happened.
- 03/22/2021
|
Leap Therapeutics Presents DKN-01 Clinical Data at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer
- CAMBRIDGE, Mass., March 22, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 as a monotherapy and in combination with paclitaxel in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 2021 Annual Meeting on Women's Cancer, being held as a virtual meeting from March 19-25, 2021.
- 03/22/2021
|
Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
- CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020.
- 03/12/2021
|
Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research
- CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the publication in Molecular Cancer Research of preclinical results from studies of human and...
- 12/22/2020
|
Leap Therapeutics Presents DKN-01 Monotherapy Data at AACR Virtual Special Endometrial Cancer Conference
- CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of clinical data from its Phase 2 clinical trial of DKN-01 in patients with...
- 11/09/2020
|
Week 46 MDA Breakout Forecast - November: Short-Term Picks To Give You An Edge
- Two new breakout stocks for Week 46 with better than 10% short-term upside potential. This past week three out of four stocks gained more than 10% closing with gains to Friday with AVNS +8.54%, IMVT +14.96%, YY +10.85% with top average portfolio gains of 11.14%.
- 11/07/2020
|
Leap Therapeutics Reports Second Quarter 2020 Financial Results
- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2020.
- 08/13/2020
|
Leap Therapeutics Inc (NASDAQ:LPTX) Receives $5.50 Average Target Price from Brokerages
- Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have earned an average rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that […]
- 07/27/2020
|
3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)
- The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that these stocks are risky in nature, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Given this volatility, it can be difficult to gauge which healthcare stocks are primed to outperform. That’s where Wall Street analysts come in.Using TipRanks’ database, we identified three trading for less than $5 per share that not only earned a “Strong Buy” consensus rating from the analyst community, but also boasts triple-digit upside potential.Leap Therapeutics Inc. (LPTX)Developing innovative monoclonal antibodies, Leap Therapeutics targets key cellular pathways that enable cancer to grow and proliferate, known as cancer cell signaling, and pathways that help the body’s immune system identify and treat cancer. Given its promising technology and $1.77 share price, the company has been impressing analysts left and right.Calling LPTX a “diamond in the rough”, Piper Sandler analyst Tyler Van Buren points to the initial results of its lead candidate, DKN-01 (anti-DKK1 mAb), as a single agent and combination therapy in highly pretreated esophagogastric and gynecologic cancer patients as contributing to his optimistic stance. Looking at the monotherapy cohorts, the candidate generated a complete response (CR) and three partial responses (PRs), which demonstrates the mechanism is active, in Van Buren’s opinion. He added, “In combination with PD-1 or chemotherapy, DKK1-high patients or those with Wnt-activating mutations derived significantly greater clinical benefit compared to DKK1-low patients.”What are the implications of the data? Van Buren argued, “We believe the anti-DKK1 approach has a clear biological rationale, DKK1 expression is a promising biomarker and prospectively-defined indicator for poor prognosis, and the fact that DKN-01 has monotherapy activity is impressive and unique. Considering the data generated to date, we believe DKN-01 has the potential to improve outcomes in historically hard-to-treat solid tumor types.”Adding to the good news, LPTX counts BeiGene as a partner in the advancement of DKN-01 in combination with tislelizumab (PD-1) in esophagogastric cancer. There’s also an ongoing Phase 2 DKN-01/chemo combo study in 1L gynecologic cancers, with data slated for release by year end, and several ISTs in other difficult tumor types are progressing on schedule.To this end, should the therapy ultimately receive approval, Van Buren believes DKN-01 could launch in the U.S. in 2025 in the r/r setting and in the 1L setting in 2026, with the estimate for peak sales landing at roughly $900 million in gastric cancer.To this end, Van Buren rates LPTX an Overweight (i.e. Buy) along with a $6 price target. Should the target be met, a twelve-month gain in the shape of a whopping 240% could be in store. (To watch Van Buren’s track record, click here) Judging by the consensus breakdown, other analysts also like what they’re seeing. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $6.33 average price target, the upside potential comes in at 259%. (See LPTX stock analysis on TipRanks)Corvus Pharmaceuticals (CRVS)Focused on the development of medicines with precise mechanisms of action, Corvus Pharmaceuticals wants to improve the lives of patients with difficult-to-treat cancers like refractory renal cell carcinoma and non-small cell lung cancer. Currently going for $4.09 apiece, several members of the Street think that the share price presents investors with an opportunity to get in on the action.While boasting expertise in oncology, H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that the company is also targeting COVID-19. On July 7, CRVS unveiled an additional clinical program for CPI-006, its patented monoclonal antibody targeting CD73, and initiated a Phase 1 study to evaluate the drug in COVID-19 patients. The study follows up the release of evidence that supports CPI-006’s immunostimulatory activity, with the candidate also producing strong results in a COVID-19 patient who is a cohort member in the Phase 1 study evaluating CPI-006 as a treatment for advanced tumors.Taking a closer look at the early results, after dosing, B cells were activated, resulting in surface marker changes consistent with B cell differentiation and isotype class switching. “Separately, in cancer patients, CPI-006 treatment led to elevated serum levels of memory B cells, the cells responsible for long-term immunity,” Ramakanth noted.The analyst added, “In an ongoing Phase 1 study with CPI-006 as a treatment for advanced tumors, a patient with advanced metastatic non-small cell lung cancer who was confirmed positive for COVID-19 infection post CPI-006 treatment developed high titers of anti-SARS-CoV-2 IgG and IgM of 1:102,400 and 1:3,200, respectively, within six weeks post a single dose. The patient tested negative for the virus at the six-week time point... Additionally, serum levels of memory B cells in this COVID-19 patient increased to 30% of total B cell count, from 16%, which is consistent with the levels seen in cancer patients treated with CPI-006.”All of the above led Ramakanth to conclude that the candidate has significant potential as a COVID-19 treatment. Therefore, if the COVID-19 study, which is designed to enroll up to 30 COVID-19 patients with mild to moderate symptoms, meets the required endpoints, a randomized study of CPI-006 will be initiated. These results could potentially support a BLA filing for FDA approval, in Ramakanth’s opinion.In line with his optimistic take, Ramakanth stayed with the bulls. In addition to reiterating a Buy recommendation, he left the price target at $10, suggesting 145% upside potential. (To watch Ramakanth’s track record, click here) The bulls have it on this one. Out of 3 total reviews published in the last three months, all 3 analysts rated the stock a Buy. So, CRVS gets a unanimous Strong Buy consensus rating. Given the $8.33 average price target, shares could soar nearly 100% in the next twelve months. (See Corvus stock analysis on TipRanks)Eyenovia Inc. (EYEN)Last but not least, we come across Eyenovia, which uses its cutting-edge microdosing technology to develop treatments for conditions that affect the eyes. With some of its clinical activities back up and running, its $2.70 share price could reflect an attractive entry point.Recently, EYEN revealed that it had resumed patient enrollment at nearly all clinical sites for its Phase 3 CHAPERONE study, after the COVID-19 pandemic forced the company to temporarily halt enrollment. The study is evaluating the safety and efficacy of MicroPine for the reduction of progressive myopia using its atropine topical micro-formulation delivered by the Optejet dispenser.Even though the health crisis spurred headwinds, the follow-up and monitoring of previously-enrolled CHAPERONE patients via telemedicine and remote monitoring processes were able to progress.Writing for Ladenburg, analyst Matthew Kaplan pointed out, “The company has shared positive preliminary usability data of the Optejet, where patients as young as 5 years old were able to self-administer treatment. Importantly, EYEN has initiated strategies to maintain the integrity of the data for patients already enrolled in the trial with the institution of virtual monitoring.” Additionally, he argues that top-line data could potentially still come by 2023.On top of this, the company’s pipeline includes its MicroLine program designed for the presbyopia (farsightedness) indication. Currently, there aren’t any FDA approved treatments available for the condition, and the standard of care is reading glasses or contact lenses. While the program’s two Phase 3 studies have been delayed thanks to COVID-19, management believes it will be able to initiate the trials in 2020. Kaplan added, “Initial market research confirmed the company’s commercial assumptions that high-income middle-aged subjects would be receptive to MicroLine.”If that wasn’t enough, its MicroStat product has demonstrated compelling results in both the MIST-1 and MIST-2 studies. As a result, EYEN plans to assess the manufacturing and stability batches as well as submit an NDA during 2H20. “With Eyenovia’s plan to price MicroStat on parity to the current eye drops based on their market research, and with an estimated 80 million dilated eye exams and ~4 million surgeries requiring dilation performed each year, we believe it could represent a significant market opportunity for MicroStat,” Kaplan commented.As Kaplan sees the company’s strategy as being very much intact, the deal is sealed. To this end, he kept a Buy rating and $19 price target on the stock. This target conveys his confidence in EYEN’s ability to climb 604% higher in the next year. (To watch Kaplan’s track record, click here) The rest of the Street agrees with Kaplan. Only Buy ratings, 3, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $13, the average price target puts the upside potential at 381%. (See EYEN stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/20/2020
|
Merck KGaA (OTCMKTS:MKGAF) vs. Amarin (OTCMKTS:AMRN) Head-To-Head Contrast
- Amarin (NASDAQ:AMRN) and Merck KGaA (OTCMKTS:MKGAF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 44.4% of Amarin shares are owned by institutional investors. 2.8% of Amarin shares […]
- 07/01/2020
|
Benzinga's Top Upgrades, Downgrades For June 29, 2020
- Upgrades * SunTrust Robinson Humphrey changed the rating for CoreLogic Inc (NYSE: CLGX) from Hold to Buy. In the first quarter, CoreLogic showed an EPS of $0.76, compared to $0.45 from the year-ago quarter. The stock has a 52-week-high of $68.40 and a 52-week-low of $24.69. CoreLogic's stock last closed at $67.95 per share. * For Big Lots Inc (NYSE: BIG), Loop Capital upgraded the stock from Hold to Buy. For the first quarter, Big Lots had an EPS of $1.26, compared to year-ago quarter EPS of $0.92. The stock has a 52-week-high of $44.90 and a 52-week-low of $10.12. Big Lots's stock last closed at $43.02 per share. * For Southwest Airlines Co (NYSE: LUV), Goldman Sachs upgraded the stock from Sell to Buy. For the first quarter, Southwest Airlines had an EPS of ($0.15), compared to year-ago quarter EPS of $0.70. The stock has a 52-week-high of $58.83 and a 52-week-low of $22.46. Southwest Airlines's stock last closed at $31.96 per share. * Raymond James upgraded the stock for CDW Corp (NASDAQ: CDW) from Market Perform to Outperform. In the first quarter, CDW showed an EPS of $1.38, compared to $1.24 from the year-ago quarter. The stock has a 52-week-high of $146.09 and a 52-week-low of $73.39. CDW's stock last closed at $108.49 per share. * Evercore ISI Group changed the rating for Chart Industries Inc (NASDAQ: GTLS) from In-Line to Outperform. In the first quarter, Chart Industries showed an EPS of $0.57, compared to $0.39 from the year-ago quarter. The stock has a 52-week-high of $78.80 and a 52-week-low of $15.00. Chart Industries's stock last closed at $45.22 per share. * For The Middleby Corp (NASDAQ: MIDD), KeyBanc upgraded the stock from Sector Weight to Overweight. The Middleby earned $1.33 in the first quarter, compared to $1.38 in the year-ago quarter. The stock has a 52-week-high of $142.98 and a 52-week-low of $41.73. The Middleby's stock last closed at $72.98 per share. Downgrades * Credit Suisse changed the rating for AMC Entertainment Holdings Inc (NYSE: AMC) from Neutral to Underperform. For the first quarter, AMC Entertainment had an EPS of ($2.22), compared to year-ago quarter EPS of ($1.25). The stock has a 52-week-high of $12.49 and a 52-week-low of $1.95. AMC Entertainment's stock last closed at $4.16 per share. * For Beyond Meat Inc (NASDAQ: BYND), Barclays downgraded the stock from Overweight to Underweight. Beyond Meat earned $0.03 in the first quarter, compared to ($0.14) in the year-ago quarter. The stock has a 52-week-high of $239.71 and a 52-week-low of $48.18. Beyond Meat's stock last closed at $141.68 per share. * For Cinemark Holdings Inc (NYSE: CNK), Credit Suisse downgraded the stock from Outperform to Neutral. For the first quarter, Cinemark Hldgs had an EPS of ($0.37), compared to year-ago quarter EPS of $0.28. The stock has a 52-week-high of $41.60 and a 52-week-low of $5.71. Cinemark Hldgs's stock last closed at $11.39 per share. * Wells Fargo downgraded the stock for CoreLogic Inc (NYSE: CLGX) from Overweight to Equal-Weight. CoreLogic earned $0.76 in the first quarter, compared to $0.45 in the year-ago quarter. The stock has a 52-week-high of $68.40 and a 52-week-low of $24.69. CoreLogic's stock last closed at $67.95 per share. * For Diamondback Energy Inc (NASDAQ: FANG), BMO Capital downgraded the stock from Outperform to Market Perform. In the first quarter, Diamondback Energy showed an EPS of $1.45, compared to $1.39 from the year-ago quarter. The stock has a 52-week-high of $111.84 and a 52-week-low of $14.55. Diamondback Energy's stock last closed at $41.13 per share. * For Fiserv Inc (NASDAQ: FISV), Oppenheimer downgraded the stock from Outperform to Perform. Fiserv earned $0.99 in the first quarter, compared to $0.84 in the year-ago quarter. The stock has a 52-week-high of $125.05 and a 52-week-low of $73.50. Fiserv's stock last closed at $94.92 per share. * Goldman Sachs changed the rating for Neurocrine Biosciences Inc (NASDAQ: NBIX) from Buy to Neutral. For the first quarter, Neurocrine Biosciences had an EPS of $0.82, compared to year-ago quarter EPS of ($1.12). The stock has a 52-week-high of $131.00 and a 52-week-low of $72.14. Neurocrine Biosciences's stock last closed at $130.36 per share. * BMO Capital changed the rating for Pilgrims Pride Corp (NASDAQ: PPC) from Outperform to Market Perform. In the first quarter, Pilgrims Pride showed an EPS of $0.18, compared to $0.35 from the year-ago quarter. The stock has a 52-week-high of $33.67 and a 52-week-low of $15.75. Pilgrims Pride's stock last closed at $16.69 per share. * Guggenheim downgraded the stock for Spotify Technology SA (NYSE: SPOT) from Neutral to Sell. In the first quarter, Spotify Technology showed an EPS of ($0.22), compared to ($0.90) from the year-ago quarter. The stock has a 52-week-high of $271.71 and a 52-week-low of $109.18. Spotify Technology's stock last closed at $265.05 per share. * HC Wainwright & Co. downgraded the stock for Inovio Pharmaceuticals Inc (NASDAQ: INO) from Buy to Neutral. For the first quarter, Inovio Pharmaceuticals had an EPS of ($0.26), compared to year-ago quarter EPS of ($0.30). The stock has a 52-week-high of $33.79 and a 52-week-low of $1.92. Inovio Pharmaceuticals's stock last closed at $29.98 per share. Initiations * Piper Sandler initiated coverage on Leap Therapeutics Inc (NASDAQ: LPTX) with an Overweight rating. The price target for Leap Therapeutics is set at $6.00. For the first quarter, Leap Therapeutics had an EPS of ($0.55), compared to year-ago quarter EPS of ($0.47). The stock has a 52-week-high of $3.18 and a 52-week-low of $0.57. Leap Therapeutics's stock last closed at $2.19 per share. * Jefferies initiated coverage on Madison Square Garden Entertainment Corp (NYSE: MSGE) with a Buy rating. The price target for Madison Square Garden is set at $100.00. The stock has a 52-week-high of $87.20 and a 52-week-low of $62.50. Madison Square Garden's stock last closed at $72.65 per share. * HSBC initiated coverage on Otis Worldwide Corp (NYSE: OTIS) with a Reduce rating. The price target for Otis Worldwide is set at $44.00. The stock has a 52-week-high of $61.46 and a 52-week-low of $41.26. Otis Worldwide's stock last closed at $55.82 per share. * Cowen & Co. initiated coverage on Pliant Therapeutics Inc (NASDAQ: PLRX) with an Outperform rating. The stock has a 52-week-high of $31.99 and a 52-week-low of $21.05. Pliant Therapeutics's stock last closed at $31.72 per share. * JP Morgan initiated coverage on Warner Music Group Corp (NASDAQ: WMG) with an Overweight rating. The price target for Warner Music Group is set at $40.00. The stock has a 52-week-high of $34.76 and a 52-week-low of $26.99. Warner Music Group's stock last closed at $30.47 per share. * With a rating of Sector Perform, RBC Capital initiated coverage on ZoomInfo Technologies Inc (NASDAQ: ZI). The price target is set at $50.00 for ZoomInfo Technologies. The stock has a 52-week-high of $64.40 and a 52-week-low of $32.10. ZoomInfo Technologies's stock last closed at $51.57 per share. * B of A Securities initiated coverage on ZoomInfo Technologies Inc (NASDAQ: ZI) with a Buy rating. The price target for ZoomInfo Technologies is set at $60.00. The stock has a 52-week-high of $64.40 and a 52-week-low of $32.10. ZoomInfo Technologies's stock last closed at $51.57 per share. * Evercore ISI Group initiated coverage on Warner Music Group Corp (NASDAQ: WMG) with an Outperform rating. The price target for Warner Music Group is set at $36.00. The stock has a 52-week-high of $34.76 and a 52-week-low of $26.99. Warner Music Group's stock last closed at $30.47 per share. * SVB Leerink initiated coverage on Nuance Communications Inc (NASDAQ: NUAN) with an Outperform rating. The price target for Nuance Communications is set at $31.00. For the second quarter, Nuance Communications had an EPS of $0.21, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $26.01 and a 52-week-low of $13.51. Nuance Communications's stock last closed at $25.39 per share. * HC Wainwright & Co. initiated coverage on Arena Pharmaceuticals Inc (NASDAQ: ARNA) with a Buy rating. The price target for Arena Pharmaceuticals is set at $90.00. In the first quarter, Arena Pharmaceuticals showed an EPS of ($2.00), compared to $12.34 from the year-ago quarter. The stock has a 52-week-high of $69.75 and a 52-week-low of $32.95. Arena Pharmaceuticals's stock last closed at $65.92 per share. * Needham initiated coverage on Enphase Energy Inc (NASDAQ: ENPH) with a Buy rating. The price target for Enphase Energy is set at $53.00. In the first quarter, Enphase Energy showed an EPS of $0.38, compared to $0.08 from the year-ago quarter. The stock has a 52-week-high of $70.36 and a 52-week-low of $16.32. Enphase Energy's stock last closed at $45.30 per share.See more from Benzinga * 11 Communication Services Stocks Moving In Monday's Pre-Market Session * 5 Basic Materials Stocks Moving In Monday's Pre-Market Session * 16 Industrials Stocks Moving In Monday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/29/2020
|
Leap Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an additional 3,375,000 shares of common stock pursuant to the full exercise of the underwriters' option to purchase additional shares from Leap's previously announced public offering. After giving effect to the full exercise of the option, the aggregate gross proceeds to Leap from this offering were approximately $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap.
- 06/25/2020
|
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants
- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 20,250,000 shares of common stock and pre-funded warrants to purchase up to 2,250,000 shares of its common stock. The gross proceeds to Leap from this offering were approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by Leap.
- 06/22/2020
|
Leap Therapeutics (NASDAQ:LPTX) Shares Gap Down to $2.04
- Leap Therapeutics Inc (NASDAQ:LPTX)’s share price gapped down before the market opened on Friday . The stock had previously closed at $2.06, but opened at $2.04. Leap Therapeutics shares last traded at $2.05, with a volume of 68,233 shares trading hands. A number of brokerages have commented on LPTX. Zacks Investment Research lowered shares of […]
- 06/21/2020
|
Leap Therapeutics Announces Pricing of $45 Million of Common Stock and Pre-Funded Warrants
- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $1.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Leap from this offering are expected to be approximately $45 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Leap. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. In addition, Leap has granted the underwriters a 30-day option to purchase up to an aggregate of an additional 3,375,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The offering is expected to close on or about June 22, 2020, subject to satisfaction of customary closing conditions.
- 06/18/2020
|
Leap Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock, Leap intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the securities offered in the public offering. The offering is subject to market, regulatory, and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 06/17/2020
|
Apogenix to Present at AACR Virtual Annual Meeting II | | IT Business Net
- HEIDELBERG, GERMANY / ACCESSWIRE / June 17, 2020 / Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the AACR Virtual Annual
- 06/17/2020
|
Company News for Jun 15, 2020
- Companies in the news are: EMAN, LPTX, VISL, CLPS
- 06/15/2020
|
Leap Therapeutics (LPTX) Soars: Stock Adds 8.3% in Session
- Leap Therapeutics (LPTX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
- 06/15/2020
|
Hedge Funds Have Never Been This Bullish On LEAP THERAPEUTICS, INC. (LPTX)
- In this article we will check out the progression of hedge fund sentiment towards LEAP THERAPEUTICS, INC. (NASDAQ:LPTX) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]
- 06/12/2020
|
The Daily Biotech Pulse: FDA Nod For Viela, 3 IPOs And Hematology Congress Presentations
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 11) * ADC Therapeutics SA (NYSE: ADCT) * Applied Molecular Transport Inc (NASDAQ: AMTI) (IPOed June 5) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Novo Nordisk A/S (NYSE: NVO)(announced a deal to buy privately held Corvidia Therapeutics that is developing therapies for cardio-renal diseases for up to $2.1 billion) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(announced commencement of first human trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19) * Sarepta Therapeutics Inc (NASDAQ: SRPT) * Zynex Inc. (NASDAQ: ZYXI) (announced addition to the S&P; SmallCap 600 Index)Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 11) * Ayala Pharmaceuticals Inc (NASDAQ: AYLA) * CALLIDITAS THER/S ADR (NASDAQ: CALT)(IPOed June 5) * Evofem Biosciences Inc (NASDAQ: EVFM) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Vaccinex Inc (NASDAQ: VCNX)Stocks In Focus Leap Therapeutics's Cancer Drug Gets Orphan Drug Designation Leap Therapeutics Inc (NASDAQ: LPTX) said the FDA U.S. Food and granted orphan drug designation for its DKN-01 for the treatment of gastric and gastroesophageal junction cancer. The company said DKN-01 is currently being evaluated in Phase 1/2 and Phase 2 clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers.The stock climbed 28.44% to $2.40 in after-hours trading.Virtual European Hematology Association Congress Presentations Agios Pharmaceuticals Inc (NASDAQ: AGIO) reported interim data from its ongoing Phase 2 study evaluating single agent mitapivat in non-transfusion-dependent α\- and β-thalassemia, which showed it induced hemoglobin increase of 1 g/dl or more in 12 of 13 evaluable patients, including 4 of 4 α-thalassemia patients during Weeks 4-12. The company said 7 of the 8 evaluable patients achieved sustained hemoglobin response during Weeks 12-24.The company noted that one Grade 3 adverse events of renal dysfunction was reported related to the treatment post cut-off date but was resolved upon treatment discontinuation.The stock was sliding 9.79% to $45.71 in pre-market trading.Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP) presented at the EHA meeting new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia, or TDT, and severe sickle cell disease, or SCD.Long-term follow-up data from a TDT patient showed at 15 months after CTX001 infusion, the patient was transfusion independent and had appreciable hemoglobin levels. The second patient was transfusion independent at five months.New data from one SCD patient showed nine months after CTX001 infusion, the patient was free of vaso-occlusive crises, was transfusion independent and had an increase in hemoglobin levels.Vertex shares were edging up 0.42% to $265 and Crispr was advancing 2.18% to $61 in pre-market trading.Editas Medicine Inc (NASDAQ: EDIT) announced results from a pre-clinical, proof-of-concept study of EDIT-301 in SCD, with both in-vitro and in-vivo studies revealing several desirable properties.The stock was rising 4.40% to $26.11 in pre-market trading.Viela Receives FDA Approval For Neurological Autoimmune Disorder Drug Viela Bio Inc (NASDAQ: VIE) said the FDA approved its Uplizna for the treatment of adult patients with neuromyelitis optica spectrum disorder, or NMOSD, who are anti-AQP4 antibody positive as a twice-a-year maintenance regimen following initial doses. Approximately 80% of all patients with NMOSD test positive for anti-AQP4 antibodies. The company is expects to launch the drug commercially in June.In pre-market trading, the stock was gaining 6.55% to $54.82.Quidel Gets $635,000 BARDA Funding For 4-Virus Point-Of-Care Test Quidel Corporation (NASDAQ: QDEL) said it has received funding from the Biomedical Advanced Research and Development Authority, or BARDA, to support the development of a point-of-care diagnostic assay that potentially tests for four respiratory viruses: SARS-CoV-2, Influenza A, Influenza B, and Respiratory Syncytial Virus. The respiratory virus panel would be developed to run on Quidel's Sofia 2 flagship instrument.The company said funding began May 29, 2020, and will run through April 2021, totaling approximately $635,000. The goal of the funding, according to the company, is to achieve an Emergency Use Authorization for the test within the funding period.FDA Approves Mylan-Biocon's Diabetes Drug Mylan NV (NASDAQ: MYL) along with its Indian partner Biocon said the FDA approved their Semglee - insulin glargine injection - in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi SA's (NASDAQ: SNY) Lantus and is approved for the same indications.Mylan shares were adding 3.37% to $16.85 in pre-market trading.On The Radar Clinical Readouts/Presentations Principia Biopharma is due to present at the American Academy of Dermatology Virtual Meeting Experience, full data set presentation from the Phase 2 Part B pemphigus trial with its investigational drug rilzabrutinib.Oramed Pharmaceuticals, Inc. (NASDAQ: ORMP) will present at the American Diabetes Association 80th Scientific Sessions posters on oral insulin ORMD-0801's effects on glucose parameters in uncontrolled Type 2 diabetes, oral insulin-induced reduction in liver fat content in Type 2 diabetic patients with non-alcoholic steatohepatitis and evening oral insulin glycemic effects in uncontrolled Type 2 diabetes patientsIPO Vaxcyte, Inc., a company developing vaccines to prevent or treat the most common and deadly infectious diseases, priced its upsized initial public offering, or IPO, of 15.625 million shares of its common stock at $16 per share. The shares will begin trading on the Nasdaq under the ticker symbol PCVX.La Jolla, California-based Avidity Biosciences, Inc. priced its upsized IPO of 14.4 million shares at $18 per share compared to the estimated price range of $17-$18. The shares of the biopharma, which develops a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates to treat a wide range of serious diseases, will be listed on the Nasdaq under the ticker symbol RNA.Cambridge, Massachusetts-based gene therapy company Generation Bio Co priced its IPO of 10.53 million shares at $19 per share compared to the estimated price range of $18-$19. The company's shares will begin trading on the Nasdaq under the ticker symbol GBIO.See more from Benzinga * The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO * The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset * The Daily Biotech Pulse: Soleno Flunks Late-Stage Study, Sanofi Strikes Breast Cancer Partnership, NanoViricides Shortlists Coronavirus Treatment Candidates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 06/12/2020
|
Leap Therapeutics Announces Oprhan Drug Designation of DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer. DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, a modulator of Wnt/Beta-catenin signaling.
- 06/11/2020
|
Leap Therapeutics Announces Changes to Virtual Format and Time for 2020 Annual Meeting of Stockholders
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, due to public health and safety concerns related to the outbreak of the novel coronavirus ("COVID-19"), and to support the health and well-being of its stockholders, employees and others, the Company is changing its 2020 Annual Meeting of Stockholders (the "Annual Meeting") to a virtual-only format. The virtual Annual Meeting is expected to provide stockholders with the same rights and opportunities to participate as they would have had at an in-person meeting. Stockholders can submit questions related to the matters to be voted on at the virtual Annual Meeting by using the instructions on the virtual meeting website listed below.
- 06/11/2020
|
Analyst Estimates: Here's What Brokers Think Of Leap Therapeutics, Inc. (NASDAQ:LPTX) After Its First-Quarter Report
- Leap Therapeutics, Inc. (NASDAQ:LPTX) missed earnings with its latest quarterly results, disappointing...
- 05/16/2020
|
Leap Therapeutics Reports First Quarter 2020 Financial Results
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended March 31, 2020.
- 05/14/2020
|
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its anti-Dickkopf-1 (DKK1) antibody, as both a monotherapy and in combination with paclitaxel chemotherapy in patients with advanced gynecological malignancies. Leap will host a conference call with Rebecca Arend, M.D., Assistant Professor and Associate Scientist, Gynecologic Oncology Clinic, The University of Alabama at Birmingham School of Medicine Comprehensive Cancer Center Experimental Therapeutics Program, today, April 23, 2020, at 8:30 A.M. EDT to discuss the data.
- 04/23/2020
|
Financial Contrast: Leap Therapeutics (NASDAQ:LPTX) & Tiziana Life Sciences (NASDAQ:TLSA)
- Leap Therapeutics (NASDAQ:LPTX) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Profitability This table compares Leap Therapeutics and Tiziana Life Sciences’ net margins, return on […]
- 04/22/2020
|
One Thing To Remember About The Leap Therapeutics, Inc. (NASDAQ:LPTX) Share Price
- If you're interested in Leap Therapeutics, Inc. (NASDAQ:LPTX), then you might want to consider its beta (a measure of...
- 04/07/2020
|
Leap Therapeutics Announces Executive Leadership Changes
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced changes to the Company's Executive Leadership Team. All changes to the Board of Directors are effective immediately. Other management changes will take effect April 1, 2020, and include the following:
- 03/18/2020
|
Leap Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2019.
- 03/16/2020
|
Analyzing Homology Medicines (NASDAQ:FIXX) & Leap Therapeutics (NASDAQ:LPTX)
- Homology Medicines (NASDAQ:FIXX) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations. Volatility & Risk Homology Medicines has a beta of 0.28, meaning that its share price […]
- 03/04/2020
|
Head to Head Review: Leap Therapeutics (NASDAQ:LPTX) vs. Esperion Therapeutics (NASDAQ:ESPR)
- Leap Therapeutics (NASDAQ:LPTX) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Volatility and Risk Leap Therapeutics has a beta of 1.37, suggesting that its stock price […]
- 03/03/2020
|
The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...
- 02/20/2020
|
S, TMUS among premarket gainers
- Sprint (NYSE:S) +74% after judge approves T-Mobile merger.Rexahn Pharmaceuticals (NASDAQ:REXN) +25%.ZK International Group (NASDAQ:ZKIN) +21% on supplying stainless steel pipe and fitting products for
- 02/11/2020
|
Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting
- Leap Therapeutics, Inc. (Nasdaq: LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or recurrent esophagogastric cancer (EGC) at the 2020 ASCO GI annual meeting.
- 01/23/2020
|
Leap Therapeutics Announces Closing of Previously Announced Equity Financing
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously announced equity financing to issue 1,421,801 shares of newly designated Series A mandatorily convertible preferred stock to a lead institutional investor, at a price of $10.54 per share, and an aggregate of 1,137,442 shares of newly designated Series B mandatorily convertible preferred stock to BeiGene and Perceptive Advisors, at a price of $10.55 per share. The preferred stock price reflects a common stock equivalent price of $1.055 per share, the closing price for Leap's common stock on the Nasdaq Global Market on the day of pricing, January 2, 2020 and, in the case of the Series A mandatorily convertible preferred stock, reflects a per share reduction equal to the exercise price of the pre-funded warrant issued upon conversion of the Series A mandatorily convertible preferred stock. The holder of Series A mandatorily convertible preferred stock also received a share of a newly designated special voting preferred stock that will entitle it to elect one member of Leap's Board of Directors.
- 01/07/2020
|
Leap Therapeutics Surges on License Agreement With BieGene
- Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
- 01/06/2020
|
Cash-strapped biotech signs deal with Chinese drugmaker BeiGene
- A small Cambridge biotech is getting a much-needed infusion of cash, signing what its CEO called a “transformative” collaboration deal with Chinese drugmaker BeiGene Ltd.
- 01/03/2020
|
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand. Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for a $27 million equity financing with BeiGene and two institutional investors.
- 01/03/2020
|
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
- Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- 11/15/2019
|
Leap Therapeutics Reports Third Quarter 2019 Financial Results
- - DKN-01 data continues to show robust activity, including a monotherapy complete response, in cancer patients with high DKK-1 expression and Wnt signaling alterations - De-prioritizing further development ...
- 11/14/2019
|
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
- Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
- 09/27/2019
|
Use Rising P/E Strategy to Grab 5 Winning Stocks
- Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
- 09/26/2019
|
The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering
- The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 19.) 10X Genomics Inc (NASDAQ: TXG ) (listed its ...
- 09/20/2019
|
Do Directors Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares?
- The big shareholder groups in Leap Therapeutics, Inc. (NASDAQ:LPTX) have power over the company. Insiders often own a...
- 09/19/2019
|
